According to a 2016 industry survey, 80% of respondents agreed that Phase I studies are becoming more complex.
We know clinical trial complexity is increasing, so let’s investigate how it's happening across most dimensions of trial planning and management.
Discoveries driven by genomic data could dramatically increase the number of biomarkers available for use in clinical trials.
The world's oncology pipeline is rapidly growing, with nearly 40% of the global clinical pipeline focused on immuno-oncology.
When optimizing your study practice, it is vital to evaluate every trial phase in context.